Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NRSN | US
-0.01
-1.57%
Healthcare
Biotechnology
30/06/2024
02/06/2026
0.80
0.84
0.84
0.78
NeuroSense Therapeutics Ltd. a clinical-stage biotechnology company focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya Israel.
View LessLow Debt to Equity (< 0.25)
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
71.5%1 month
66.1%3 months
62.7%6 months
77.5%-
-
4.15
-0.02
0.02
-1.16
-
-
-11.69M
15.85M
15.85M
-
-
-
-
-494.84
1.04
1.83
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.18
Range1M
0.24
Range3M
0.42
Rel. volume
0.93
Price X volume
93.01K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Inhibikase Therapeutics Inc. | IKT | Biotechnology | 1.7 | 16.96M | -0.58% | n/a | 3.49% |
| Aligos Therapeutics Inc | ALGS | Biotechnology | 5.25 | 16.78M | -1.87% | n/a | 14.63% |
| iBio Inc | IBIO | Biotechnology | 1.76 | 16.08M | -6.88% | n/a | 20.92% |
| VistaGen Therapeutics Inc | VTGN | Biotechnology | 0.58 | 15.69M | -10.42% | n/a | 1.90% |
| Zivo Bioscience Inc | ZIVO | Biotechnology | 4.45 | 15.40M | n/a | -25.20% | |
| Adial Pharmaceuticals Inc | ADIL | Biotechnology | 2.36 | 15.12M | -3.67% | n/a | 0.00% |
| 22nd Century Group Inc | XXII | Biotechnology | 0.48 | 15.09M | -17.24% | n/a | -1072.15% |
| ICU | ICU | Biotechnology | 3.53 | 14.80M | -3.02% | n/a | -45.50% |
| CytoMed Therapeutics Limited Ordinary Shares | GDTC | Biotechnology | 1.14 | 13.16M | -0.10% | n/a | 3.98% |
| Kezar Life Sciences Inc | KZR | Biotechnology | 0.18 | 13.13M | 5.88% | n/a | 11.69% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.11 | 16.22M | -2.63% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.4275 | 8.26M | -0.47% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.71 | 4.37M | 1.18% | n/a | 17.32% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0063 | 580.95K | 12.50% | n/a | -37.05% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.4821 | 265.64K | -11.54% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.16 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.15 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 62.70 | - | Par |
| Debt to Equity | -0.02 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 15.85M | - | Emerging |